Literatur: Dabigatran

Als Hinweis auf potentielle weitere Informationsquellen. Kein Anspruch auf Vollständigkeit.

 

Dabigatran

  • 1. Alban S, “Pharmacological Strategies for Inhibition of Thrombin Activity,” Curr Pharm Des, 2008, 14(12):1152-75. [PubMed 18473863]
  • 2. Blech S, Ebner T, Ludwig-Schwellinger E, et al, “The Metabolism and Disposition of The Oral Direct Thrombin Inhibitor, Dabigatran, in Humans,” Drug Metab Dispos, 2008, 36(2):386-99. [PubMed 18006647]
  • 3. Connolly SJ, Ezekowitz MD, Yusuf S, et al, “Dabigatran Versus Warfarin in Patients With Atrial Fibrillation,” N Engl J Med, 2009, 361(12):1139-51 [PubMed 19717844]
  • 4. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al, “Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects,” Circulation, 2011, 124(14):1573-9. [PubMed 21900088]
  • 5. Eikelboom JW, Wallentin L, Connolly SJ, et al, “Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial,” Circulation, 2011, 123(21):2363-72. [PubMed 21576658]
  • 6. Ezekowitz MD, Reilly PA, Nehmiz G, et al, “Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study),” Am J Cardiol, 2007, 100(9):1419-26. [PubMed 17950801]
  • 7. Eriksson BI, Dahl OE, Kurth AA, et al, “Oral Dabigatran Etexilate Versus Subcutaneous Enoxaparin for the Prevention of Venous Thromboembolism after Total Knee Replacement: The RE-MODEL Randomized Trial,” J Thromb Haemost, 2007, 5(11):2178-85. [PubMed 17764540]
  • 8. Eriksson BI, Dahl OE, Rosencher N, et al, “Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism after Total Hip Replacement: A Randomised, Double-Blind, Non-Inferiority Trial,” Lancet, 2007, 370(9591):949-56. [PubMed 17869635]
  • 9. Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest, 2012, 141(2 Suppl):7-47. [PubMed 22315257]
  • 10. Legrand M, Mateo J, Aribaud A, et al, “The Use of Dabigatran in Elderly Patients,” Arch Intern Med, 2011, 171(14):1285-6. [PubMed 21788545]
  • 11. Nutescu EA, Shapiro NL, and Chevalier A, “New Anticoagulant Agents: Direct Thrombin Inhibitors,” Cardiol Clin, 2008, 26(2): 169-87. [PubMed 18406993]
  • 12. Skanes AC, Healey JS, Cairns JA, et al, “Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,” Can J Cardiol, 2012, 28(2):125-36. [PubMed 22433576]
  • 13. Stangier J, Eriksson BI, Dahl OE, et al, “Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement,” J Clin Pharmacol, 2005, 45(5): 555-63. [PubMed 15831779]
  • 14. Stangier J, Rathgen K, Stähle H, et al, “Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate,” Clin Pharmacokinet, 2010, 49(4):259-68. [PubMed 20214409]
  • 15. van Ryn J, Stangier J, Haertter S, et al, “Dabigatran Etexilate – A Novel, Reversible, Oral Direct Thrombin Inhibitor: Interpretation of Coagulation Assays and Reversal of Anticoagulant Activity,” Thromb Haemost, 2010, 103(6):1116-27. [PubMed 20352166]
  • 16. Wallentin L, Yusuf S, Ezekowitz MD, et al, “Efficacy and Safety of Dabigatran Compared With Warfarin at Different Levels of International Normalised Ratio Control for Stroke Prevention in Atrial Fibrillation: An Analysis of the RE-LY Trial,” Lancet, 2010, 376(9745):975-83. [PubMed 20801496]
  • 17. Wann SL, Curtis AB, Ellenbogen KA, et al, “2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Circulation, 2011, 123(10):1144-50. [PubMed 21321155]
  • 18. Wann SL, Curtis AB, January CT, et al, “2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Circulation, 2011, 123(1):104-23. [PubMed 21173346]
  • 19. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011; 123:1436. [PubMed 21464059]
  • 20. Alban S, "Pharmacological Strategies for Inhibition of Thrombin Activity," Curr Pharm Des, 2008, 14(12):1152-75. [PubMed 18473863]
  • 21. American Geriatrics Society 2012 Beers Criteria Update Expert Panel, "American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults," J Am Geriatr Soc, 2012, 60(4):616-31. [PubMed 22376048]
  • 22. Blech S, Ebner T, Ludwig-Schwellinger E, et al, "The Metabolism and Disposition of The Oral Direct Thrombin Inhibitor, Dabigatran, in Humans," Drug Metab Dispos, 2008, 36(2):386-99. [PubMed 18006647]
  • 23. Connolly SJ, Ezekowitz MD, Yusuf S, et al, "Dabigatran Versus Warfarin in Patients With Atrial Fibrillation," N Engl J Med, 2009, 361(12):1139-51 [PubMed 19717844]
  • 24. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al, "Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects," Circulation, 2011, 124(14):1573-9. [PubMed 21900088]
  • 25. Eikelboom JW, Wallentin L, Connolly SJ, et al, "Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial," Circulation, 2011, 123(21):2363-72. [PubMed 21576658]
  • 26. Ezekowitz MD, Reilly PA, Nehmiz G, et al, "Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study)," Am J Cardiol, 2007, 100(9):1419-26. [PubMed 17950801]
  • 27. Eriksson BI, Dahl OE, Kurth AA, et al, "Oral Dabigatran Etexilate Versus Subcutaneous Enoxaparin for the Prevention of Venous Thromboembolism after Total Knee Replacement: The RE-MODEL Randomized Trial," J Thromb Haemost, 2007, 5(11):2178-85. [PubMed 17764540]
  • 28. Eriksson BI, Dahl OE, Rosencher N, et al, "Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism after Total Hip Replacement: A Randomised, Double-Blind, Non-Inferiority Trial," Lancet, 2007, 370(9591):949-56. [PubMed 17869635]
  • 29. Guyatt GH, Akl EA, Crowther M, et al, "Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines," Chest, 2012, 141(2 Suppl):7-47. [PubMed 22315257]
  • 30. Legrand M, Mateo J, Aribaud A, et al, "The Use of Dabigatran in Elderly Patients," Arch Intern Med, 2011, 171(14):1285-6. [PubMed 21788545]
  • 31. Nutescu EA, Shapiro NL, and Chevalier A, "New Anticoagulant Agents: Direct Thrombin Inhibitors," Cardiol Clin, 2008, 26(2): 169-87. [PubMed 18406993]
  • 32. Skanes AC, Healey JS, Cairns JA, et al, "Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control," Can J Cardiol, 2012, 28(2):125-36. [PubMed 22433576]
  • 33. Stangier J, Eriksson BI, Dahl OE, et al, "Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement," J Clin Pharmacol, 2005, 45(5): 555-63. [PubMed 15831779]
  • 34. Stangier J, Rathgen K, Stähle H, et al, "Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate," Clin Pharmacokinet, 2010, 49(4):259-68. [PubMed 20214409]
  • 35. van Ryn J, Stangier J, Haertter S, et al, "Dabigatran Etexilate - A Novel, Reversible, Oral Direct Thrombin Inhibitor: Interpretation of Coagulation Assays and Reversal of Anticoagulant Activity," Thromb Haemost, 2010, 103(6):1116-27. [PubMed 20352166]
  • 36. Wallentin L, Yusuf S, Ezekowitz MD, et al, "Efficacy and Safety of Dabigatran Compared With Warfarin at Different Levels of International Normalised Ratio Control for Stroke Prevention in Atrial Fibrillation: An Analysis of the RE-LY Trial," Lancet, 2010, 376(9745):975-83. [PubMed 20801496]
  • 37. Wann SL, Curtis AB, Ellenbogen KA, et al, "2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines," Circulation, 2011, 123(10):1144-50. [PubMed 21321155]
  • 38. Wann SL, Curtis AB, January CT, et al, "2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines," Circulation, 2011, 123(1):104-23. [PubMed 21173346]

 

  top |

 

 
© 2018 Prof. Dr. J. Braun